Radius Health (NASDAQ:RDUS) Upgraded at BidaskClub

Radius Health (NASDAQ:RDUS) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday, January 10th.

Other research analysts have also issued research reports about the stock. ValuEngine raised shares of Radius Health from a “strong sell” rating to a “sell” rating in a research note on Friday, December 1st. Citigroup started coverage on shares of Radius Health in a research note on Wednesday, December 6th. They issued a “neutral” rating and a $30.00 price target for the company. Zacks Investment Research downgraded shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Cantor Fitzgerald reiterated a “buy” rating and issued a $58.00 price target on shares of Radius Health in a research note on Friday, November 3rd. Finally, Jefferies Group decreased their price target on shares of Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a research note on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $48.00.

Radius Health (RDUS) traded down $0.60 during trading on Wednesday, reaching $34.10. 922,100 shares of the company traded hands, compared to its average volume of 970,020. Radius Health has a 52-week low of $24.66 and a 52-week high of $49.16. The firm has a market capitalization of $1,520.00, a PE ratio of -6.28 and a beta of 1.10. The company has a current ratio of 12.87, a quick ratio of 12.79 and a debt-to-equity ratio of 0.53.

Radius Health (NASDAQ:RDUS) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.03). The business had revenue of $13.50 million for the quarter, compared to analyst estimates of $6.90 million. During the same period in the previous year, the company posted ($1.07) EPS. research analysts anticipate that Radius Health will post -5.57 earnings per share for the current fiscal year.

In other Radius Health news, major shareholder Growth N. V. Biotech bought 50,000 shares of the business’s stock in a transaction dated Tuesday, November 14th. The shares were acquired at an average cost of $26.25 per share, with a total value of $1,312,500.00. Following the acquisition, the insider now directly owns 5,698,799 shares of the company’s stock, valued at approximately $149,593,473.75. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Brent Hatzis-Schoch acquired 1,778 shares of the company’s stock in a transaction on Friday, November 10th. The stock was purchased at an average cost of $28.09 per share, for a total transaction of $49,944.02. Following the completion of the purchase, the vice president now directly owns 2,278 shares in the company, valued at approximately $63,989.02. The disclosure for this purchase can be found here. Insiders bought a total of 158,578 shares of company stock worth $4,659,916 over the last ninety days. Corporate insiders own 15.00% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in RDUS. Cubist Systematic Strategies LLC purchased a new stake in shares of Radius Health during the 3rd quarter worth $110,000. Sei Investments Co. boosted its position in shares of Radius Health by 27.7% during the 2nd quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 690 shares in the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of Radius Health by 19.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock worth $148,000 after purchasing an additional 541 shares in the last quarter. Advisor Group Inc. boosted its position in shares of Radius Health by 267.2% during the 2nd quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 2,888 shares in the last quarter. Finally, Amalgamated Bank purchased a new stake in shares of Radius Health during the 2nd quarter worth $211,000.

COPYRIGHT VIOLATION WARNING: “Radius Health (NASDAQ:RDUS) Upgraded at BidaskClub” was published by BBNS and is the sole property of of BBNS. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://baseballnewssource.com/markets/radius-health-rdus-lifted-to-hold-at-bidaskclub/1822796.html.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.